An overview of the
current data from PsoProtectMe

Current Data

We are committed to sharing data and are delighted to provide open access to summary information from PsoProtectMe. These data are preliminary so should not be used to inform clinical decision making.

Click here to read our research paper detailing PsoProtect data. A summary can be found on the Psoriasis Association website here.

Our research paper detailing shielding behaviour can be found here. A summary can also be found on the Psoriasis Association website here.

Our research paper detailing factors associated with worsening of psoriasis in the pandemic can be found here. A summary can be found on the Psoriasis Association website here.

See our full list of research publications here.

0
PsoProtectMe surveys completed

Summary data from PsoProtectMe’s first 5181 participants.

Participants per country (≥10 participants):

Country Participants Country Participants
Argentina 227 Netherlands 47
Australia 41 Norway 30
Brazil 156 Panama 11
Canada 65 Paraguay 13
Chile 466 Peru 19
Denmark 55 Philippines 59
Dominican Republic 10 Poland 104
France 14 Portugal 295
Greece 14 Singapore 16
Hong Kong 18 South Africa 17
India 54 Spain 80
Ireland 62 Sweden 63
Italy 62 United Kingdom 2540
Japan 109 United States 349
Malaysia 11 Other (<10) 164
Mexico 10

Average age: 45 years (range 3-91)

Average BMI: 26.8 kg/m2

Type of psoriasis: 4263 plaque psoriasis, 1082 guttate psoriasis, 279 pustular psoriasis, 113 erythrodema

Gender:

Smoking status:

Coexisting psoriatic arthritis:

Type of psoriasis treatment:

Psoriasis severity change during the pandemic:

Have you been diagnosed with or thought you had COVID-19?

Did you go to hospital A&E due to your COVID-19?

Did you stay in hospital due to your COVID-19?

Has your COVID-19 infection got better?